Cosmos Health forecasts Oliv18 to add over $6 million in annual U.S. revenue within 12-18 months.
The outlook implies about $4.3 million in gross profit, based on an expected gross margin of about 72%.
Rollout starts with direct-to-consumer e-commerce, followed by expansion into selected retail channels.
The model assumes pricing, sales volumes, repeat purchases, and distribution growth tied to execution of commercialization plans.
Target markets: U.S. cardiovascular supplements at $2.11 billion in 2024, projected to reach $3.27 billion by 2030; antioxidants at $1.66 billion in 2025, projected to reach $3.18 billion by 2035.
COSM•
